Talk:Gemcitabine

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Gemcitabine.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Wrong name change

If you are going to change the name, shouldn't you do it right, and rename it gemcitabine hydrochloride? Gene Nygaard 22:11, 1 Jun 2005 (UTC)

No, the consensus at Wikipedia:WikiProject Drugs is that we use only the active compound, and not any chemical additives (compare imatinib mesylate). JFW | T@lk 23:23, 1 Jun 2005 (UTC)

hai... hw many stages for preparation of this drug?? hyderabady_chemist —Preceding unsigned comment added by 68.102.250.74 (talk) 21:39, 15 August 2010 (UTC)[reply]

Why no efficacy discussion?

This could benefit from a discussion of studies indicating the efficacy for various types of cancers and various stages. — Preceding unsigned comment added by R Stillwater (talk • contribs) 03:47, 23 September 2011 (UTC)[reply]

ESPAC-4 results in pancreatic cancer

Trial Sets New Standard for Pancreatic Cancer - Adjuvant combination almost doubled 5-year survival discusses ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. Trial terminated early due to significant improvement in median survival. Will try to edit in when find the right place. - Rod57 (talk) 20:27, 15 June 2016 (UTC)[reply]